B-type Natriuretic Peptide (BNP) Research: What 12,830 Studies Show (2026) | RetatrutideCompare

B-type Natriuretic Peptide (BNP) — 12,830 studies indexed on PubMed. Activates NPR-A, elevating cGMP. Vasodilation, natriuresis, suppression of RAAS. Half-life: ~20 minutes (recombinant Nesiritide). FDA status: Withdrawn in US (2018).

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on B-type Natriuretic Peptide (BNP)?

There are approximately 12,830 studies indexed on PubMed that mention B-type Natriuretic Peptide (BNP) (Nesiritide, Natrecor), based on a search last updated 2026-06-18.

Is B-type Natriuretic Peptide (BNP) FDA-approved?

FDA status: Withdrawn in US (2018).

How does B-type Natriuretic Peptide (BNP) work?

Activates NPR-A, elevating cGMP. Vasodilation, natriuresis, suppression of RAAS.

Reference facts

Also known as: Nesiritide, Natrecor
Category: Cardiovascular & Natriuretic
Mechanism of action: Activates NPR-A, elevating cGMP. Vasodilation, natriuresis, suppression of RAAS.
Targets: NPR-A
Indications under research or approved: Acute decompensated heart failure (Nesiritide; withdrawn 2018 in US for commercial reasons after ASCEND-HF efficacy concerns)
Regulatory status (reference entry): Withdrawn in US (2018)
Half-life: ~20 minutes (recombinant Nesiritide)
Sequence: SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH
Sequence notes: 32-residue peptide with disulfide bridge Cys10-Cys26.
Molecular weight (Da): 3464
First reported: 1988

Primary References

ASCEND-HF, NEJM 2011

Explore research articles about B-type Natriuretic Peptide (BNP)

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.